---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-341270"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2026-08-10T11:40:52+00:00"
generated_at: "2026-08-10T11:45:06.226673+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Jazz to acquire Actio Biosciences for $820M upfront, up to $500M milestones

## Summary
- Jazz to acquire Actio Biosciences for $820M upfront plus up to $500M in approval/sales milestones.
- Lead asset ABS-1230: first-in-class KCNT1 inhibitor for KCNT1+ epilepsy, no FDA-approved therapies.
- ABS-1230 has FDA Fast Track, Rare Pediatric Disease, Orphan Drug designations; accepted into RDEP program.
- Transaction expected to close Q4 2026; funded via cash on hand and existing facilities.
- Actio spins out new entity with TRPV4 inhibitor ABS-0871; Jazz takes minority stake.

## SEC filing metadata
- accession: 0001193125-26-341270
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2026-08-10T11:40:52+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000119312526341270/0001193125-26-341270-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000119312526341270/d106596d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-341270
- JSON: https://secwatch.observer/filing/0001193125-26-341270.json
- Plain text: https://secwatch.observer/filing/0001193125-26-341270.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.